The company develops implantable medical devices using its unique hydrogel technology, catering to various markets such as spine, orthopedics, neuro, and vascular surgery. Their products, including EnGuard, GelStix, and GelFix, provide solutions for low back pain caused by degenerative disc disease. Replication Medical is currently planning a clinical trial in the U.S. for FDA approval of GelStix and expanding its marketing efforts for GelStix in the European Union. With new management, the company aims to offer efficient treatment options for patients suffering from degenerative spinal disc disease.